WARREN SCOTT PEAR
Medical Practice in Philadelphia, PA
License number
Pennsylvania MD060527L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Philadelphia, PA 19130
Personal information
See more information about WARREN SCOTT PEAR at radaris.comName
Address
Phone
2128 Green St, Philadelphia, PA 19130
34 E Walnut Ln, Philadelphia, PA 19144
34 Walnut St, Philadelphia, PA 19144
820 Ringgold St, Philadelphia, PA 19130
2128 Green St, Philadelphia, PA 19130
Professional information
Warren Pear, Philadelphia PA
Work:
Hospital of the University of PA
3400 Spruce St, Philadelphia, PA 19175
3400 Spruce St, Philadelphia, PA 19175
Dr. Warren S Pear, Philadelphia PA - MD (Doctor of Medicine)
Specialties:
Clinical Pathology
Address:
3400 Spruce St, Philadelphia 19104
(215) 662-6503 (Phone)
(215) 662-6503 (Phone)
Certifications:
Clinical Pathology, 1996
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
3400 Spruce St, Philadelphia 19104
Hospital of the University of Pennsylvania
3400 Spruce St, Philadelphia 19104
Hospital of the University of Pennsylvania
3400 Spruce St, Philadelphia 19104
Education:
Medical School
University of Rochester
Graduated: 1989
Brigham and Women's Hospital
University of Rochester
Graduated: 1989
Brigham and Women's Hospital
Warren S Pear, Philadelphia PA
Specialties:
Pathologist
Address:
3400 Spruce St, Philadelphia, PA 19104
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Modulating Lymphoid Commitment And Survival
US Patent:
2003018, Sep 25, 2003
Filed:
Mar 10, 2003
Appl. No.:
10/385591
Inventors:
Warren Pear - Philadelphia PA, US
David Allman - Havertown PA, US
Yiping He - Philadelphia PA, US
David Izon - Wembley, AU
Jon Aster - Lexington MA, US
David Allman - Havertown PA, US
Yiping He - Philadelphia PA, US
David Izon - Wembley, AU
Jon Aster - Lexington MA, US
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
Provided are methods for manipulating aspects of lymphopoiesis by modulating and controlling Notch signaling, thereby providing treatment for diseases of the immune system. Accordingly, there are provided methods for selectively modulating T cell fate commitment of a common lymphoid progenitor at the expense of B cell fate commitment, and in the converse for selectively modulating B cell fate commitment of a common lymphoid progenitor at the expense of T cell fate commitment. Also provided are methods for treating patients suffering from a disease or disorder of T cell origin, or conversely of B cell origin. Further provided are methods for selectively killing B cells in a committed population of B cells, such as in a patient suffering from B cell leukemia or lymphoma; as well as methods for selectively killing T cells in a committed population of T cells such as in a patient suffering from diseases of T cell origin.
Diagnostic And Therapeutic Utility Of Tribbles-2 In Human Cancers
US Patent:
2011001, Jan 20, 2011
Filed:
Jan 19, 2007
Appl. No.:
12/087949
Inventors:
Warren S. Pear - Philadelphia PA, US
Karen Keeshan - Philadephia PA, US
Yiping He - Phildephia PA, US
Karen Keeshan - Philadephia PA, US
Yiping He - Phildephia PA, US
International Classification:
A61K 39/395, C12Q 1/68, G01N 33/68, C12N 5/078, A61K 38/02, A61K 31/7105, A61K 31/7088, A61P 35/02
US Classification:
4241731, 435 6, 435 724, 435375, 514 11, 514 44 A, 514 44 R, 514 196
Abstract:
Provided are methods for the diagnosis and treatment of acute myelogenous leukemia. In particular, the present invention relates to the use of Trib2 polynucleotides and polypeptides for the diagnosis and treatment of acute myelogenous leukemia (AML) by assessing myeloid cells of a patient, or malignancies associated with Trib2, C/EBPαp30 or C/EBPαp42, such as AML or lung cancer, by assessing hematopoietic stem cells of the patient.